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Both hypertension and coronary artery spasm (CAS) are
associated with endothelial dysfunction. Thus, a higher
incidence of CAS is expected in hypertensive patients.
We evaluated the impact of hypertension on CAS with
intracoronary acetylcholine (ACh) provocation test. A
total of 986 patients (685 hypertensive patients vs 301
normotensive patients) who underwent coronary angio-
graphy with ACh provocation test were enrolled. ACh
was injected into the left coronary artery in incremental
doses of 20, 50 and 100lgmin
 1. Significant CAS was
defined as a transient 470% luminal narrowing with
concurrent chest pain and/or ST-segment changes.
Although the incidences of significant ACh-induced
CAS were similar between hypertensive and normoten-
sive patients (35.8 vs 39.2%, P¼0.303), multivariate
logistic analysis showed that hypertension was nega-
tively associated with ACh-induced CAS (odds ratio: 0.70,
95% confidence interval: 0.51–0.94, P¼0.020). The angio-
graphic characteristics of ACh-induced CAS were similar
between these two groups. Subgroup analysis regarding
the impact of the status of blood pressure control on CAS
showed that hypertensive patients with controlled blood
pressure had a significantly higher incidence of CAS than
those with uncontrolled blood pressure (45.2 vs 27.9%,
Po0.001), and that uncontrolled blood pressure was
negatively associated with ACh-induced CAS (odds ratio:
0.56, 95% confidence interval: 0.40–0.79, P¼0.001). In
conclusion, despite the expected endothelial dysfunc-
tion, hypertension and uncontrolled blood pressure are
negatively associated with CAS, suggesting that the
mechanisms and risk factors of CAS may be significantly
different from those of coronary artery disease.
Journal of Human Hypertension (2010) 24, 77–85;
doi:10.1038/jhh.2009.40; published online 21 May 2009
Keywords: acetylcholine; coronary artery spasm; blood pressure control
Introduction
Hypertension represents one of the most common
conditions associated with increased cardiovascular
risk, including stroke, myocardial infarction and heart
failure.
1 Numerous experimental and clinical research
data have shown that hypertension is associated
with significant endothelial dysfunction, which may
represent a major pathogenic link between hyperten-
sion and coronary artery disease.
2,3
Coronary artery spasm (CAS) plays an important
role in the pathogenesis of vasospatic angina and
acute coronary syndrome. Some earlier studies
have suggested that patients with CAS have a
disturbance in the endothelial function of the
coronary arteries.
4–6 Thus, it is reasonable to
speculate that patients with hypertension may have
a higher incidence of significant CAS. However,
only several studies designed to analyse the multi-
ple risk factors for CAS have briefly evaluated the
impact of hypertension on CAS, and no earlier study
to date has analysed the impact of the status of blood
pressure control on CAS.
7–9 Therefore, in this study,
we evaluated the impact of hypertension and the
status of blood pressure control on CAS with
intracoronary acetylcholine (ACh) provocation test
in a series of Korean hypertensive patients.
Materials and methods
Study population
The study flow chart was shown in Figure 1. A total
of 986 patients, 685 patients with hypertension and
301 patients with normotension were enrolled into
this study. The study protocol was approved by the
institutional review board at Korea University, Guro
Hospital (Seoul, Korea) and written informed consent
was obtained from every patient before study entry.
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Coronary artery spasm was induced by intracoron-
ary injection of ACh after diagnostic catheterization
in the morning. The details of the method were
reported earlier.
10,11 In brief, nitrates, calcium chan-
nel blockers (CCBs), b-blockers, angiotensin-con-
verting enzyme inhibitors, angiotensin II receptor
blockers and other vasodilators or vasoconstrictors
were withheld at least 72h before coronary angio-
graphy. ACh was injected in incremental doses of 20
(A1), 50 (A2) and 100 (A3) mg into the left coronary
artery over a 1min period with 5min intervals to the
maximum tolerated dose under continuous monitor-
ing of electrocardiogram (ECG) and blood pressure.
Angiography was repeated after each ACh dose.
After that, an intracoronary infusion with 0.2mg
nitroglycerin was given. Angiography was then
performed 2min later. If focal or diffuse significant
vasoconstriction of coronary arteries was induced
with any dose of ACh, the ACh infusion was
stopped. End-systolic and end-diastolic images for
each segment of the left coronary artery were chosen
according to the corresponding points on the
electrocardiographic trace (QRS onset or end of
T wave) and analysed using the proper quantitative
coronary angiographic system of the catheterization
laboratory (BH-3000, Philips, Amsterdam, The
Netherlands). The quantitative measuring variable
was described as percent change from baseline on an
angiogram. Two expert observers analysed the
angiographic images at right anterior oblique cranial
views and the evaluated QCA data were entered into
the database. The percent diameter change was
measured at the most severely narrowed site of the
significantly spastic artery.
Study definitions
Brachial blood pressure was measured in triplicate in
the right arm with a cuff and mercury sphygmoman-
ometer after the patient rested in a seated position
for 5min. The average of the last two measurements
was used as brachial blood pressure. Pulse pressure
was calculated as the difference between systolic and
diastolic pressures. Hypertension was diagnosed
according to the following criteria: (1) a history of
diagnosed hypertension status and treatment with
medications, diet and/or exercises; (2) systolic blood
pressure X140mmHg or diastolic blood pressure
X90mmHg on at least two occasions; (3) current use
of antihypertensive pharmacological therapy to con-
trol hypertension.
12 In this retrospective study, we
reviewed all the hypertensive patients’ in-hospital
medical records about blood pressure before the
temporal cessation of vasodilators; if the hypertensive
patient’s systolic blood pressure was X140mmHg or
diastolic blood pressure was X90mmHg with the
treatment of antihypertensive agents on calm occa-
sions, he or she was identified as an uncontrolled
blood pressure patient or else as a controlled blood
pressure patient.
Hyperlipidaemia was defined as total cholesterol
level X200mg per 100ml or current treatment with
lipid-lowering drugs. Current cigarette smoking
was defined as active smoking within the past 12
months. Diabetes was defined as fasting blood
glucose X126mg per 100ml, or the use of hypogly-
caemic agents or insulin. Peripheral arterial disease
(PAD) was defined as a claudication symptom with
ankle brachial indexes o0.90, and/or a claudication
symptom with any angiographic finding of signifi-
cant lesion in the peripheral artery and/or sympto-
matic carotid or subclavian arterial disease
documented by image studies.
During the ACh provocation test, significant CAS
was defined as a 470% decrease in the arterial
luminal diameter with concurrent chest pain and/or
ST-segment elevation or depression X1mm. Myo-
cardial bridge was considered when the character-
istic phasic compression of the coronary artery had a
430% decrease in diameter on the angiogram after
intracoronary nitroglycerin infusion.
10,11
Statistical analysis
All the statistical analyses were performed using
SPSS 11.0 (SPSS Inc., Chicago, IL, USA). For
continuous variables, differences between groups
were evaluated by unpaired t-test or Mann–Whitney
rank-sum test. For discrete variables, differences
were expressed as counts and percentages and
analysed with w
2 (or Fisher’s exact) test between
A total of 4 872 patients underwent coronary angiography
from March 2004 to February 2007 in Cardiovascular
Center of Korea University Guro Hospital. 
301 patients with
normotension 
685 patients with
hypertension 
Patients were excluded if they had one of the following conditions:
An angiographically visible atherosclerotic lesion, previous acute
coronary syndrome, previous coronary artery bypass graft,
previous percutaneous coronary intervention, advanced heart failure
(New York Heart Association functional class III or IV), underlying
hypertrophic cardiomyopathy, previous cerebrovascular disease, or
any other serious medical conditions such as an increased creatinine
level ≥ 2 mg/dL. 
Among them, 1 201 patients who had chest pain
without significant coronary lesion (luminal narrowing
<50%) underwent coronary angiography with
intracoronary acetylcholine provocation test. 
A total of 986 patients were finally enrolled
Figure 1 Study flow chart.
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sion analysis, which included baseline confounding
factors, was used for assessing the independent
impact of hypertension or the status of blood
pressure control on ACh-induced significant CAS.
A two-tailed P-value of o0.05 was considered to be
statistically significant. Data were expressed as
mean±standard deviation (s.d.).
Results
Impact of hypertension on coronary artery spasm
The baseline clinical characteristics of normotensive
and hypertensive patients are presented in Table 1.
Patients with hypertension were older, had higher
body mass index, systolic and diastolic blood
pressure, pulse pressure and more frequently had
diabetes, hyperlipidaemia and PAD, but less fre-
quently had current smoking compared with those
with normotension. Accordingly, hypertensive
patients had higher rates of use aspirin, b-blockers,
CCBs, angiotensin-converting enzyme inhibitors,
angiotensin II receptor blockers and statins than
did normotensive patients. Even though there was a
trend towards a higher level of blood triglyceride in
hypertensive patients, the blood levels of total
cholesterol, low- and high-density lipoprotein cho-
lesterol were similar between these two groups,
reflecting the higher rate of use statins in hyperten-
sive patients.
The characteristics of ACh provocation test were
presented in Table 2. The reference diameters (mm)
(1.84±0.49 vs 1.81±0.47, P¼0.504) and diameter
narrowing (%) (37.64±34.42 vs 39.39±32.75,
P¼0.729) of the coronary artery after ACh infusion
were similar between patients with and without
hypertension. Furthermore, the reference diameters
of the coronary artery after nitroglycerin infusion
were also similar between these two groups (mm)
(2.58±0.54 vs 2.66±0.59, P¼0.119). On account of
the above results, the incidences of ACh-induced
significant CAS did not differ significantly between
patients with and without hypertension (35.8 vs
39.2%, P¼0.303). During ACh provocation test, the
incidences of ST-segment change, chest pain, atrio-
ventricular block and myocardial bridge were
similar between these two groups.
In patients who had significant CAS, the char-
acteristics of CAS were also similar between
patients with and without hypertension, including
the maximal tolerable doses of ACh, spasm
types (focal vs diffuse) and spasm vessel number
(Table 3).
As shown in Figure 2, the univariate logistic
analysis in the general study population showed
that ageing, male, hyperlipidaemia, current smok-
ing, PAD and myocardial bridge were risk factors
for ACh-induced significant CAS. However, multi-
variate logistic analysis showed that besides
ageing, male, PAD and myocardial bridge, hyper-
tension was an independent predictor, too.
Hypertension was negatively associated with ACh-
induced CAS in multivariate logistic analysis
(odds ratio: 0.70, 95% confidence interval: 0.51–
0.94, P¼0.020).
Table 1 Baseline clinical characteristics of the general study population
Variables NTN (n¼301) HTN (n¼685) P-value
Male, n (%) 155 (51.5) 327 (47.7) 0.277
Age (years) 50.45±12.20 55.71±11.93 o0.001
Body mass index (kgm
 2) 23.38±3.53 24.25±3.14 0.002
Diabetes mellitus, n (%) 20 (6.6) 86 (12.6) 0.006
Hyperlipidemia, n (%) 9 (3.0) 119 (17.4) o0.001
Current smoking, n (%) 87 (28.9) 144 (21.0) 0.007
Family history of coronary artery disease, n (%) 20 (6.6) 42 (6.1) 0.760
Peripheral arterial disease, n (%) 3 (1.0) 78 (11.4) o0.001
Systolic blood pressure (mmHg) 119.91±11.02 145.68±21.04 o0.001
Diastolic blood pressure (mmHg) 73.41±7.23 87.47±11.65 o0.001
Pulse pressure (mmHg) 46.50±8.78 58.20±15.71 o0.001
Total cholesterol (mg per 100ml) 172.04±38.30 176.51±39.15 0.109
Triglyceride (mg per 100ml) 121.86±79.37 134.67±96.14 0.064
Low-density lipoprotein cholesterol (mg per 100ml) 111.84±35.82 114.76±57.03 0.565
High-density lipoprotein cholesterol (mg per 100ml) 51.50±14.00 52.40±17.96 0.482
Aspirin, n (%) 41 (13.6) 180 (26.3) o0.001
Cilostazol, n (%) 8 (2.7) 13 (1.9) 0.447
b-Blockers, n (%) 14 (4.7) 62 (9.1) 0.017
Calcium channel blockers, n (%) 115 (38.2) 323 (47.2) 0.009
Angiotensin-converting enzyme inhibitors, n (%) 5 (1.7) 32 (4.7) 0.022
Angiotensin II receptor blockers, n (%) 11 (3.7) 94 (13.7) o0.001
Nitrates, n (%) 90 (29.9) 174 (25.4) 0.142
Nicorandil, n (%) 29 (9.6) 71 (10.4) 0.726
Statins, n (%) 37 (12.3) 134 (19.6) 0.005
Abbreviations: NTN, normotension; HTN, hypertension.
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coronary artery spasm in hypertensive patients
The baseline clinical characteristics of hypertensive
patients with and without controlled blood pressure
were similar, except that hypertensive patients with
controlled blood pressure more frequently had
hyperlipidaemia and PAD, and had higher rates of
use nitrates and CCBs but a lower rate of use
Table 2 Characteristics of ACh provocation test in general study population
Variables NTN (n¼301) HTN (n¼685) P-value
Reference diameter after NTG infusion (mm) 2.66±0.59 2.58±0.54 0.119
Reference diameter after ACh infusion (mm) 1.81±0.47 1.84±0.49 0.504
Diameter narrowing after ACh infusion (%) 39.39±32.75 37.64±34.42 0.729
Acetylcholine-induced significant CAS, n (%) 118 (39.2) 245 (35.8) 0.303
ST-segment change, n (%) 18 (6.0) 43 (6.3) 0.858
Chest pain, n (%) 137 (45.5) 284 (41.5) 0.236
Atrioventricular block, n (%) 73 (24.3) 161 (23.5) 0.799
Myocardial bridge, n (%) 73 (24.3) 163 (23.8) 0.877
Abbreviations: NTG, nitroglycerine; ACh, acetylcholine; CAS, coronary artery spasm.
Table 3 Characteristics of acetylcholine provocation test in patients with significant coronary artery spasm
Variables, n (%) NTN (n¼118) HTN (n¼245) P-value
Maximal tolerable dose of acetylcholine
A1 (20mgmin
 1) 11 (9.3) 18 (7.3) 0.516
A2 (50mgmin
 1) 63 (53.4) 140 (57.1) 0.500
A3 (100mgmin
 1) 44 (37.3) 87 (35.5) 0.741
Spasm types
Focal 14 (11.9) 40 (16.3) 0.263
Diffuse 104 (88.1) 205 (83.7) 0.263
Spasm vessel number
One vessel 58 (49.2) 122 (49.8) 0.909
Multivessel 60 (50.8) 123 (50.2) 0.909
Figure 2 Multivariate logistic analysis of the predictors for acetylcholine-induced significant coronary artery spasm in the general study
population. E: unadjusted odds ratio; ’: adjusted odds ratio.
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uncontrolled blood pressure (Table 4).
The characteristics of ACh provocation test
showed that although the diameter narrowing after
ACh infusion were similar between these two
groups, hypertensive patients with controlled blood
pressure had a significantly higher incidence of
significant CAS (45.2 vs 27.9%, Po0.001). More
patients in the controlled blood pressure group had
myocardial bridge and chest pain during the
provocation test than did those in the uncontrolled
blood pressure group (Table 5).
In the hypertensive patients who had significant
CAS, the characteristics of CAS were also similar
between patients with and without controlled blood
pressure, including spasm types (focal vs diffuse)
and spasm vessel number. However, there was a
trend towards a higher rate of significant CAS at A2
dose in hypertensive patients with controlled blood
pressure than in those without controlled blood
pressure (61.7 vs 51.0%, P¼0.093) (Table 6).
The multivariate logistic analysis, including the
aforementioned parameters, showed that uncon-
trolled blood pressure was negatively associated
with ACh-induced significant CAS (odds ratio: 0.56,
95% confidence interval: 0.40–0.79, P¼0.001)
(Figure 3).
Discussion
Numerous experimental and clinical research data
have shown that hypertension is associated with
significant endothelial dysfunction.
2 Therefore, the
association between hypertension and endothelial
dysfunction has been well established. Some studies
have suggested that CAS is also associated with
endothelial dysfunction.
4–6,13 Kugiyama et al.
5
reported that there was a deficiency in endothelial
nitric oxide activity in spasm arteries, which was
responsible for the supersensitive reaction of the
coronary artery resulting in the vasoconstrictor
Table 4 Baseline clinical characteristics of hypertensive patients with vs without controlled blood pressure
Variables Uncontrolled (n¼373) Controlled (n¼312) P-value
Male, n (%) 177 (47.5) 150 (48.1) 0.871
Age (years) 55.77±11.78 55.64±12.13 0.889
Body mass index (kgm
 2) 24.35±3.12 24.14±3.24 0.483
Diabetes mellitus, n (%) 47 (12.6) 39 (12.5) 0.968
Hyperlipidemia, n (%) 47 (12.6) 72 (23.1) o0.001
Current smoking, n (%) 78 (20.9) 66 (21.2) 0.938
Family history of coronary artery disease, n (%) 22 (5.9) 20 (6.4) 0.781
Peripheral arterial disease, n (%) 21 (5.6) 57 (18.3) o0.001
Systolic blood pressure (mmHg) 159.98±15.92 128.52±11.38 o0.001
Diastolic blood pressure (mmHg) 92.97±10.43 80.89±9.40 o0.001
Pulse pressure (mmHg) 67.02±14.39 47.64±9.49 o0.001
Total cholesterol (mg per 100ml) 178.21±40.72 174.51±37.19 0.246
Triglyceride (mg per 100ml) 130.37±84.54 139.89±108.50 0.258
Low-density lipoprotein cholesterol (mg per 100ml) 111.58±69.40 115.67±32.27 0.613
High-density lipoprotein cholesterol (mg per 100ml) 53.12±20.41 51.52±14.43 0.300
Aspirin, n (%) 96 (25.7) 84 (26.9) 0.725
Cilostazol, n (%) 7 (1.9) 6 (1.9) 0.965
b-Blockers, n (%) 36 (9.7) 26 (8.3) 0.549
Calcium channel blockers, n (%) 158 (42.4) 165 (52.9) 0.006
Angiotensin-converting enzyme inhibitors, n (%) 17 (4.6) 15 (4.8) 0.877
Angiotensin II receptor blockers, n (%) 62 (16.2) 32 (10.3) 0.016
Nitrates, n (%) 81 (21.7) 93 (29.8) 0.015
Nicorandil, n (%) 38 (10.2) 33 (10.6) 0.868
Statins, n (%) 71 (19.0) 63 (20.2) 0.704
Table 5 Characteristics of acetylcholine provocation test in hypertensive patients with vs without controlled blood pressure
Variables Uncontrolled (n¼373) Controlled (n¼312) P-value
Reference diameter after NTG infusion (mm) 2.56±0.60 2.59±0.55 0.256
Reference diameter after ACh infusion (mm) 1.87±0.41 1.73±0.43 0.314
Diameter narrowing after ACh infusion, (%) 33.51±34.87 45.62±35.71 0.243
Acetylcholine-induced significant CAS, n (%) 104 (27.9) 141 (45.2) o0.001
ST-segment change, n (%) 21 (5.6) 22 (7.1) 0.445
Chest pain, n (%) 136 (36.5) 148 (47.4) 0.004
Atrioventricular block, n (%) 93 (24.9) 76 (24.4) 0.862
Myocardial bridge, n (%) 61 (16.4) 102 (32.7) 0.001
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another study from Kugiyama et al.
6 indicated that
flow-dependent coronary dilation is impaired in
spasm arteries, partly because of a deficiency in
endothelial nitric oxide bioactivity. Recently, Yasue
et al.
13 tested whether fluvastatin, a 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor
(statin), could suppress coronary spasm based on
the hypothesis that coronary spasm is associated
with endothelial dysfunction. Their results showed
that the addition of fluvastatin 30mg per day to the
conventional CCB therapy for 6 months significantly
reduced the number of patients with ACh-induced
coronary spasm as compared with the conventional
CCB therapy. Thus, in view of the above studies,
4–6,13 it
seems reasonable to conclude that CAS is associated
with coronary endothelial dysfunction.
In this context, we tested the hypothesis that
hypertensive patients might have a higher incidence
of CAS than normotensive ones. In addition, some
earlier studies
14,15 have shown that medical treat-
ment with controlled blood pressure can signifi-
cantly reduce the incidence of cardiovascular events
in hypertensive patients. However, the impact of the
status of blood pressure control on the incidence of
CAS has not been reported yet. Therefore, we also
performed a subgroup analysis in hypertensive
patients to test the hypothesis that the controlled
blood pressure might be associated with a lower
incidence of CAS because of the potentially
improved endothelial function with medical treat-
ment. However, in contrast to our initial expecta-
tion, hypertension and uncontrolled blood pressure
were actually seen to be negatively associated with
Table 6 Characteristics of acetylcholine provocation test in hypertensive patients with significant coronary artery spasm
Variables, n (%) Uncontrolled (n¼104) Controlled (n¼141) P-value
Maximal tolerable dose of acetylcholine
A1 (20mgmin
 1) 7 (6.7) 11 (7.8) 0.751
A2 (50mgmin
 1) 53 (51.0) 87 (61.7) 0.093
A3 (100mgmin
 1) 44 (42.3) 43 (30.5) 0.056
Spasm types
Focal 19 (18.3) 21 (14.9) 0.480
Diffuse 85 (81.7) 120 (85.1) 0.480
Spasm vessel number
One vessel 52 (50.0) 70 (49.6) 0.956
Multivessel 52 (50.0) 71 (50.4) 0.956
Figure 3 Multivariate logistic analysis of the predictors for acetylcholine-induced significant coronary artery spasm in hypertensive
patients with vs without controlled blood pressure. E: unadjusted odds ratio; ’: adjusted odds ratio.
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tion test. In this study, although hypertensive and
normotensive patients had similar incidences of
ACh-induced significant CAS and diameter narrow-
ing after ACh infusion, multivariate logistic analysis
showed that hypertension was negatively associated
with ACh-induced significant CAS. The subgroup
analysis performed in hypertensive patients showed
that hypertensive patients with controlled blood
pressure had a significantly higher incidence of
CAS than those without, and that uncontrolled
blood pressure was negatively associated with
ACh-induced significant CAS. Therefore, collec-
tively, our results suggested that lower blood
pressure rather than higher blood pressure was
positively associated with CAS. Patients with
hypertension had a lower incidence of CAS com-
pared with those with normotension, and this result
seems to be driven mainly by the lower incidence of
CAS in hypertensive patients with uncontrolled
blood pressure.
The paradoxical impact of hypertension and the
status of blood pressure control on CAS might be
explained as follows. First, ACh has dual effects on
the coronary artery tone depending on their intra-
coronary concentration. The normal response to
ACh is vasodilation at small doses and vasoconstric-
tion at higher doses when the direct vasoconstrictor
effect of ACh overwhelms the stimulation of nitric
oxide release. Thus, ACh-induced CAS in this study,
we feel, does not necessarily signify endothelial
dysfunction.
16–18 Furthermore, the lack of vasodila-
tion at small doses or mild degrees of vasoconstric-
tion, which was not recognized as significant CAS,
also reflects endothelial dysfunction.
19,20 Thus, our
results do not contradict the well-established con-
cept that hypertension is closely associated with
endothelial dysfunction.
Second, earlier studies have suggested that the
pathogenesis of coronary vasospasm unassociated
with significant coronary atherosclerosis differed
from that of atherosclerosis because the major
atherosclerotic risk factors, such as hyperlipidaemia
and diabetes mellitus, were not significantly asso-
ciated with CAS.
8,21,22 Our results also supported
this and showed that hyperlipidaemia and diabetes
were not associated with CAS. Furthermore, beyond
our initial expectation, we surprisingly found that
hypertension and uncontrolled blood pressure were
negatively associated with CAS. Therefore, more
studies are needed to explore the mechanisms
behind the association between hypertension
and CAS.
Although the conventional risk factors for athero-
sclerosis such as hypertension, diabetes mellitus,
hyperlipidaemia and smoking have been well
established during the past several decades, less
has been known about the risk factors for CAS.
Several studies have analysed the risk factors for
CAS, but the results seem varied.
8,21,22 Xiang et al.
8
reported the risk factors for ACh-induced CAS and
showed that there was no significant association
between CAS and sex, age, hypertension and
positive treadmill test, but that smoking and
hyperlipidaemia were independent risk factors for
ACh-induced significant CAS. Kido et al.
21 reported
that smoking and family history in females were the
most important risk factors for CAS, whereas other
cardiovascular risk factors such as hypertension,
hyperlipidaemia and diabetes did not show signifi-
cant correlations with ACh-induced significant
CAS. Sugiishi et al.
22 also showed that smoking
was the major risk factor for CAS, but the lipid levels
and diabetes mellitus were not independent risk
factors for it.
Our present study showed that ageing, male,
peripheral artery disease and myocardial bridge
were independent risk factors for ACh-induced
significant CAS. Our earlier study showed that
myocardial bridge was significantly associated
with CAS and was independent from the other
cardiovascular risk factors.
10,11 Thus, in this study,
we co-analysed myocardial bridge with other cardi-
ovascular risk factors. Interestingly, our results
showed that hypertension and uncontrolled blood
pressure were negatively associated with ACh-
induced significant CAS. These results are consis-
tent with the results from Sugiishi et al.
22 They also
found that hypertension was negatively associated
with CAS in a multivariate logistic analysis. How-
ever, in their study, they did not analyse the impact
of the status of blood pressure control on the
incidence of CAS.
Study limitations
This study has several obvious limitations. First,
even though we minimized the confounding effects
from the baseline biases with the multivariate
logistic analysis, it is possible that some potential
confounders might have crept in. However, we
tested CAS in a relatively large study population,
which is helpful in minimizing the confounding
effects from the baseline biases. Second, angio-
graphic evaluation of the changes in epicardial
coronary diameter after the infusion of ACh as
used in this study mainly reflects the functional
status of coronary conduit vessels but not that
for coronary microcirculation because hypertension
affects not only the coronary conduit artery but
also microcirculations.
23,24 Thus, further studies
measuring not only the coronary conduit artery
spasm but also the coronary microvascular spasm in
hypertensive patients are needed. Third, although
we had carefully made the diagnosis of hyperten-
sion and thoroughly collected the information in
detail about blood pressure for every patient, we
did not collect the patient’s blood pressure during
the provocation test. However, some patients’
blood pressure level might have obviously changed
after they stopped their antihypertensive treatment.
Fortunately, no patient in this study was found
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Journal of Human Hypertensionto have cardiovascular complications because of
the provocation test and the temporal medication
cessation.
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